Apitegromab is under clinical development by Scholar Rock and currently in Phase III for Spinal Muscular Atrophy (SMA). According to GlobalData, Phase III drugs for Spinal Muscular Atrophy (SMA) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Apitegromab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apitegromab overview

Apitegromab (SRK-015) is under development for the treatment of type 2 and type 3 spinal muscular atrophy (SMA), Becker muscular dystrophy and other muscle wasting disorders (additional myostatin related disorders). It is administered through Intravenous route. The drug candidate is a niche modulator inhibiting activation of the latent myostatin precursor.

Scholar Rock overview

Scholar Rock, a subsidiary of Scholar Rock Holding Corp, operates as a biopharmaceutical company that discovers and develops novel medicines for serious diseases. Its proprietary technology platform develops new medicines, modulating supracellular activation, for the application in the treatment of fibrosis, diseases of musculoskeletal systems, and autoimmune diseases. Scholar Rock’s lead product candidate include SRK-015, a selective inhibitor which activates latent myostatin in skeletal muscle used for the treatment of spinal muscular atrophy (SMA). The company is creating a pipeline of novel product candidates for a wide range of serious diseases such as neuromuscular disorders, cancer, fibrosis, and anemia. It collaborates with various biotechnology companies for the development of its pipeline products. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Apitegromab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.